anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognised as one of the most challenging symptoms to manage. The existence of multiple factors associated with driving and maintaining fatigue, and the evidence about what improves fatigue has led to a multifaceted approach to its management. However, there are no recommendations for fatigue management in people with I-RMDs. This lack of guidance is challenging for those living with fatigue and health professionals delivering clinical care. Therefore, our aim was to develop EULAR recommendations for the management of fatigue in people with I-RMDs.
METHODS: A multidisciplinary taskforce comprising 26 members from 14 European countries was convened, and two systematic reviews were conducted. The taskforce developed the recommendations based on the systematic review of evidence supplemented with taskforce members' experience of fatigue in I-RMDs.
RESULTS: Four overarching principles (OAPs) and four recommendations were developed. OAPs include health professionals' awareness that fatigue encompasses multiple biological, psychological and social factors which should inform clinical care. Fatigue should be monitored and assessed, and people with I-RMDs should be offered management options. Recommendations include offering tailored physical activity and/or tailored psychoeducational interventions and/or, if clinically indicated, immunomodulatory treatment initiation or change. Patient-centred fatigue management should consider the individual's needs and preferences, their clinical disease activity, comorbidities and other psychosocial and contextual factors through shared decision-making.
CONCLUSIONS: These 2023 EULAR recommendations provide consensus and up-to-date guidance on fatigue management in people with I-RMDs.
The present invention relates to systems and methods for assessing the risk score of a set of users. The method is executed by a server or computing unit, and may include a step of accessing a database with tables related to one another by one or more fields, wherein the fields may be columns that are present in two or more tables to establish the relationship. The fields that relate the tables may include values for variables and/or data, or may include key data which relate the tables to one another. Furthermore, the method may include a step of receiving a form generation request or a process startup command from a terminal, which causes the server to access and/or load the tables, relating them with one another by means of the variables and/or data shared by said tables, or by means of the key data. The tables relate users to variables and/or data such as project names, questionnaires and/or diagnostic tools, medical history data, demographic variables, psychosocial variables, and any other variable or data that is relevant for assisting a user within the framework of a project, and defining their risk score data. The method further sends a form or questionnaire to the terminal, which includes fields to be completed that the operator fills in during the call with the user, wherein the fields are generated from the relationships between tables, considering variables such as pathology type of the patient, step in the assistance process, status of the assistance process, and any other type of variable and/or data that allows the required fields to be selected to obtain the variables and/or data that make it possible to obtain the risk score data. In the method, the server also obtains the value of the user's risk score data, following the relationships of the tables and executing one or more processes to determine said value based on rules, pre-set scales or processes for estimating risk score. Additionally, the present invention discloses embodiments of systems configured to execute any of the embodiments of the method disclosed herein, and discloses computer-readable means and computer programs, which when executed by one of the embodiments of the systems disclosed herein cause said system to execute any of the embodiments of the method disclosed herein.
The present invention relates to a composition for inhibiting a non-fluorescent advanced glycation end product and a use thereof. Particularly, the present invention relates to a composition for inhibiting a non-fluorescent advanced glycation end product comprising at least one strain selected from the group consisting of Lactobacillus sp. strain, Lactococcus sp. strain, Enterococcus sp. strain, Bifidobacterium sp. strain, Bacillus sp. strain, Saccharomyces sp. strain, Pediococcus sp. strain, and Leuconostoc sp. strain; and a food composition, a pharmaceutical composition, an intestinal composition, a probiotic composition, a feed composition, and a fermented product, which comprise the composition with activity of reducing the non-fluorescent advanced glycation end product. In addition, the present invention relates to a method for preparing a non-fluorescent advanced glycation end product inhibitor and a method for inhibiting a non-fluorescent advanced glycation end product.
Diabetes mellitus and obesity are growing health concerns. New pharmacologic interventions have recently begun to play a more notable role in the treatment pathway of these separate but related conditions. In particular, glucagon-like peptide-1 receptor agonists, such as semaglutides (Ozempic, Wegovy) and tirzepatide (Mounjaro), and sodium glucose co-transporter 2 inhibitors, such as dapagliflozin (Farxiga) and empagliflozin (Jardiance), have emerged as treatment options. Multiple clinical trials have demonstrated their efficacy in regulating metabolism, improving glycemic control, and managing long-term weight reduction. However, glucagon-like peptide-1 receptor agonists have also been associated with gastrointestinal side effects, including delayed gastric emptying as well as regurgitation and aspiration during general anesthesia or deep sedation, and sodium glucose co-transporter 2 inhibitors have been associated with severe diabetic ketoacidosis. Therefore, discontinuation of these medications before surgery is imperative. Given the popularity of these medications among the general public, it is essential for hand surgeons, to understand how to appropriately manage them perioperatively. The objective of this article was to review these new diabetes mellitus and weight loss medications, including their mechanisms of action, indications for use, and perioperative management guidelines. Additionally, we will take this opportunity to review perioperative guidelines for other common medications relevant to patients undergoing procedures involving the hand and upper extremity such as antithrombotic medications and rheumatoid arthritis-related immunosuppressive medications. Finally, we will describe how the electronic medical record system can be used to optimize perioperative medication management in this population.
Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
A skin exfoliating and softening composition, comprising sodium polyacrylate powder at between 5% to 70% by weight dispersed in a solution of base oil. The composition comprises sodium polyacrylate powder mixed with any suitable base oil including food grade oils, synthetic oils, natural oils or mineral oils, with added fragrances, anti-settling agents, aromatherapy oils and/or dyes. A  method of exfoliating and softening skin is also disclosed as the composition can be used o any part of the body by rubbing it over the skin to produce an exfoliating and softening effect. After rubbing the composition on the skin for a short period of time, the treated area is then placed under running water or sprayed using an appropriate atomizer which causes the sodium polyacrylate powder to gel up and help the base oil and moisture to be absorbed by the skin. The invention has exfoliating A skin exfoliating and softening composition, comprising sodium polyacrylate powder at between 5% to 70% by weight dispersed in a solution of base oil. The composition comprises sodium polyacrylate powder mixed with any suitable base oil including food grade oils, synthetic oils, natural oils or mineral oils with added fragrances, anti-settling agents, aromatherapy oils and/or dyes. A method of exfoliating and softening skin is also disclosed as the composition can be used on any part of the body by rubbing it over the skin to produce an exfoliating and softening effect. After rubbing the composition on the skin for a short period of time, the treated area is then placed under running water or sprayed using an appropriate atomizer which causes the sodium polyacrylate powder to gel 1 up and help the base oil and moisture to be absorbed by the skin. The invention has exfoliating properties by firstly removing dead skin cells from the surface of the skin and deep cleansing properties by causing the skin pores to open and sucking out moisture from the skin taking with it dirt. This allows the base of is and cleaner moisture to absorbed back into the skin leaving it feeling clean, smooth and soft. A  method of manufacturing a skin exfoliating and softening corn position is also disclosed.
Bradykinesia, a debilitating symptom characterized by impaired movement initiation and reduced speed in Parkinson's disease (PD), is associated with abnormal oscillatory activity in the motor cortex-basal ganglia circuit. We investigated the interplay between abnormal beta and gamma oscillations in relation to bradykinesia in parkinsonian rats. Our findings showed reduced movement activities in parkinsonian rats, accompanied by enhanced high beta oscillations in the motor cortex, which are closely associated with movement transitional difficulties. Additionally, gamma oscillations correlated with movement velocity in control rats but not in parkinsonian rats. We observed selective coupling between high beta oscillation phase and gamma oscillation amplitude in PD, as well as cortical high beta-broadband gamma phase-amplitude coupling (PAC) negatively influencing locomotor activities in control and PD rats. These findings suggest a collaborative role of cortical beta and gamma oscillations in facilitating movement execution, with beta oscillations being linked to movement initiation and gamma oscillations associated with movement speed. Importantly, the aberrant alterations of these oscillations are closely related to the development of bradykinesia. Furthermore, PAC hold promise as a biomarker for comprehensive assessment of movement performance in PD.
An interactive computer request processing system. In the preferred embodiment, the request processing system utilizes telephone and computer equipment to accept refill requests for patient prescriptions. The system receives information from a patient and performs prescription inquiries to a databank to determine patient information such as the status of prescriptions. The system remains operational whether or not interactive communications can be achieved with the databank. If communications are not available, the system stores the patient information. Therefore, the system always appears to the caller to be fully operational regardless of whether interactive communications are available. When communications are re-established, the databank and prescription inquiries are conducted, whereby the system validates or invalidates requests based on specified criteria. In a preferred embodiment, the system automatically attempts to notify a patient that the patient's request is invalid, thereby alerting the patient that the patient's prescription has not been filled.
Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
The epidemiological relevance of viral acute respiratory infections (ARIs) has been dramatically highlighted by COVID-19. However, other viruses cannot be neglected, such as influenza virus, respiratory syncytial virus, human adenovirus. These viruses thrive in closed spaces, influenced by human and environmental factors. High-risk closed communities are the most vulnerable settings, where the real extent of viral ARIs is often difficult to evaluate, due to the natural disease progression and case identification complexities. During the COVID-19 pandemic, wastewater-based epidemiology has demonstrated its great potential for monitoring the circulation and evolution of the virus in the environment. The "Prevention of ARIs in indoor environments and vulnerable communities" study (Stell-ARI) addresses the urgent need for integrated surveillance and early detection of ARIs within enclosed and vulnerable communities such as long-term care facilities, prisons and primary schools. The rapid transmission of ARIs in such environments underscores the importance of comprehensive surveillance strategies to minimise the risk of outbreaks and safeguard community health, enabling proactive prevention and control strategies to protect the health of vulnerable populations. This study consists of designing and validating tools for integrated clinical and environmental-based surveillance for each setting, coupled with analytical methods for environmental matrices. The clinical surveillance involves specialized questionnaires and nasopharyngeal swabs for virus identification, while the environmental surveillance includes air and surface microbiological and chemical monitoring, and virological analysis of wastewater. Integrating this information and the collection of behavioural and environmental risk factors into predictive and risk assessment models will provide a useful tool for early warning, risk assessment and informed decision-making. The study aims to integrate clinical, behavioural, and environmental data to establish and validate a predictive model and risk assessment tool for the early warning and risk management of viral ARIs in closed and vulnerable communities prior to the onset of an outbreak.
INTRODUCTION AND HYPOTHESIS: Coital incontinence (CI) is common, with a significant impact on quality of life and sexual function. This multicentre study was aimed at measuring the association between overactive bladder (OAB), stress urinary incontinence (SUI) and different aspects of CI including orgasm and penetration incontinence.
METHODS: Following ethical approval, data from the electronic Personal Assessment Questionnaire-Pelvic Floor patient-reported outcome measure was collated for Urogynaecology outpatients from seven participating UK Hospitals between April 2018 and January 2022. Data were anonymised and analysed centrally using Excel.
RESULTS: A total of 12,877 responses were obtained, of which 4,843 were valid for inclusion. 79.3% of women presented with urinary incontinence of whom 41.6% also reported CI. 96.8% of women with CI reported mixed OAB and SUI, with 2.1% and 1.1% reporting pure OAB and SUI respectively. There was a small subset (2.4%) with no overt urinary incontinence who occasionally experienced CI. Spearman's rank-order correlation demonstrated a statistically significant association between CI symptom score with both SUI (R = 0.57, p < 0.001) and OAB (R = 0.40, p < 0.001); orgasm incontinence with SUI (R = 0.49, p < 0.001) and OAB (R = 0.36, P < 0.001); penetration incontinence with SUI (R = 0.48, p < 0.001) and OAB (R = 0.35, p < 0.001).
CONCLUSIONS: Coital incontinence is experienced by 42% of women with urinary incontinence. There is a statistically significant association between both SUI and OAB with orgasm incontinence and penetration incontinence, suggesting (a) common underlying mechanism(s). Limitations of this study include the large amount of missing data and the NHS outpatient setting that limit the conclusions that can be drawn from the data.
Paired organs like eyes, ears, and lungs in humans exhibit similarities, and data from these organs often display remarkable correlations. Accounting for these correlations could enhance classification models used in predicting disease phenotypes. To our knowledge, there is limited, if any, literature addressing this topic, and existing methods do not exploit such correlations. For example, the conventional approach treats each ear as an independent observation when predicting audiometric phenotypes and is agnostic about the correlation of data from the two ears of the same person. This approach may lead to information loss and reduce the model performance. In response to this gap, particularly in the context of audiometric phenotype prediction, this paper proposes new quadratic discriminant analysis (QDA) algorithms that appropriately deal with the dependence between ears. We propose two-stage analysis strategies: (1) conducting data transformations to reduce data dimensionality before applying QDA; and (2) developing new QDA algorithms to partially utilize the dependence between phenotypes of two ears. We conducted simulation studies to compare different transformation methods and to assess the performance of different QDA algorithms. The empirical results suggested that the transformation may only be beneficial when the sample size is relatively small. Moreover, our proposed new QDA algorithms performed better than the conventional approach in both person-level and ear-level accuracy. As an illustration, we applied them to audiometric data from the Medical University of South Carolina Longitudinal Cohort Study of Age-related Hearing Loss. In addition, we developed an R package, PairQDA, to implement the proposed algorithms.
The long-term objective of this study is to enhance the treatment and outcome of anorexia nervosa (AN). Research on the treatment of AN has lagged that of other conditions, even other eating disorders such as bulimia nervosa. The focus of this study is on adolescent AN. Successful early treatment is likely to reduce the prevalence of chronic AN with its high rates of morbidity and mortality and high health care costs. The most promising treatment for adolescent AN is a specific form of family therapy called behavioral family therapy (BFT). This treatment is focused on the disordered eating behavior that characterizes AN and enables parents to refeed their child. Although there have been several small scale studies of BFT there has been no controlled comparison with another form of family therapy. Therefore we propose to use systems family therapy (SFT) which has been developed to represent the type of family therapy practiced in the community.

One hundred and sixty adolescents of both genders aged 12-18 years meeting DSM-IV criteria for anorexia nervosa will be entered to the study. Recruitment is projected to extend for 2 years. Participants will be randomly allocated to one of the two types of family therapy. Family therapy will be given for 36-weeks. For the purpose of the present study, patients will be followed for 12-months after the end of family treatment. Hence, each family will participate for approximately 2-years, with a total participation time of some 40-hours. In a sub-study blood will be drawn from those volunteering for genetic analysis focusing on the subset of non-responders to treatments.
OBJECTIVES: I. Determine the response rate and duration of response of elderly patients with advanced breast cancer treated with first-line chemotherapy with mitigated "classical" CMF (cyclophosphamide/methotrexate/fluorouracil) vs. mitoxantrone (DHAD). II. Define the morbidity of CMF and DHAD in elderly patients. III. Determine quality of life in these patients.

OUTLINE: This is a randomized study. Patients are stratified by participating institution. The first group receives oral cyclophosphamide on days 1 through 14 and intravenous methotrexate and fluorouracil on days 1 and 8. Courses repeat every 4 weeks for a maximum of 6 courses. The second group receives intravenous mitoxantrone every 3 weeks for a maximum of 8 courses. Concomitant therapy with hepatotoxic or nephrotoxic drugs (e.g., NSAIDs) or corticosteroids (even as antiemetics) is not permitted in either group. Radiotherapy is allowed provided no more than 50% of the bone marrow is irradiated and at least 1 indicator lesion is unirradiated. Patients who complete therapy are followed every 3 months until disease progression.

PROJECTED ACCRUAL: 60 patients will be accrued over approximately 1 year. If extreme differences between arms exist after entry of 30 patients, accrual may be stopped early.
Chronic kidney disease (CKD) is a general term for heterogeneous disorders affecting the structure and function of the kidney. The variation in disease expression is partly related to the cause, pathology, severity and the rate of progression. Fatigue is a well-known and frequent symptom in HD patients with a reported association with the decrease in health-related quality of life commonly found in this population. The prevalence of fatigue ranges from 60% to as high as 97% in patients on long-term renal replacement therapy. Despite this fact, health care providers are still unaware of both its presence and severity. Several methods have been proposed as a way to assess post-HD fatigue with the "time to recover (minutes) from HD" being one of them. Lindsay et al.assisted patients' responses to the single open-ended question, "How long does it take you to recover from a dialysis session?". Although post-HD fatigue commonly exists in dialysis patients, it is usually underestimated by physicians. For this reason, appropriate and early identification of symptoms and associated factors might improve the patient's quality of life. Rayner et al. found that dialysate Na was inversely associated with DRT where lowering the Na concentration in the dialysate (to 140 mEq/L) was linked to a longer DRT.
A sample identification device 100 has a database (420, fig 4) storing characteristics of a reference sample such as an allergen, in association with advice corresponding to a health issue associated with the sample, and a sensing device 200 with control circuitry configured to compare the characteristics (e.g. the optical signature) of a sample under test with the stored characteristics. The identity of the sample is determined and the associated advice is returned to a mobile terminal 300, where it may be viewed by a user. The optical signature of the allergen may be compared with stored optical signatures within the database to determine the specific allergen. The sample may be a particle, an allergen such as pollen or grass, pollution or environmental factors. The database may store location information for readings, to alert users to allergens present in specific areas.
Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Fecal impaction is a digestive system disease, that is most common in the elderly population and becomes more prevalent with increasing age. Manual removal can successfully remove the impaction in 80% of fecal impaction cases. In severe cases, endoscopy and surgery may be necessary.
CASE PRESENTATION: A 78-year-old Han Chinese man living in a nursing home was diagnosed with fecal impaction; his initial symptom was overflow diarrhea, which is a rare occurrence with regard to fecal impaction. Nevertheless, we were able to effectively treat this situation by employing a new medical device that presents a novel method for addressing fecal impaction.
CONCLUSION: Early identification of fecal impaction with atypical symptoms is crucial to provide proper emergency management. A safe and noninvasive treatment method, especially for elderly patients with fecal impaction, should be chosen.